Tofacitinib (Xeljanz® and generics) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program.
By filling out a questionnaire on a website called Your Voice, you can provide feedback about tofacitinib for the treatment of one of the following:
- Treatment of adult patients with active psoriatic arthritis (PsA) with a previous inadequate response to a disease-modifying anti-rheumatic drug (DMARD)
- Treatment of adult patients with active ankylosing spondylitis who responded inadequately to biologic disease modifying anti-rheumatic drugs (DMARDs) or when those drugs are not advised
You can give input if you are a B.C. resident and have psoriatic arthritis or ankylosing spondylitis, a caregiver to someone with psoriatic arthritis or ankylosing spondylitis, or if your group represents people who live with psoriatic arthritis or ankylosing spondylitis.
If you would like our help in providing your input, you can email your comments to feedback@jointhealth.org. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Friday, July 5 so that we may submit the questionnaire in time for the deadline.
The submission deadline is July 9, 2024. Patients and caregivers may give their input directly through the links below.
Please click on information sheet link below to learn more about tofacitinib and the questionnaire links below to let BC PharmaCare hear Your Voice:
- For psoriatic arthritis:
- To view the information sheet for tofacitinib for the treatment of psoriatic arthritis: click here
- To complete the Questionnaire as a patient, caregiver, or patient group representative: click here
- For ankylosing spondylitis:
- To view the information sheet for tofacitinib for the treatment of ankylosing spondylitis: click here
- To complete the Questionnaire as a patient, caregiver, or patient group representative: click here